Could a lung fibrosis drug stop nosebleeds in HHT?
NCT ID NCT04976036
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether nintedanib, a drug already used for lung scarring, can reduce nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT). About 48 adults with moderate to severe nosebleeds will take either nintedanib or a placebo twice daily for 16 weeks. The main goal is to see if the drug cuts monthly nosebleed time by at least 30% compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nintedanib
What this could lead to
If it works, this could provide a new treatment option to reduce the frequency and duration of nosebleeds in people with HHT.
What could go wrong
This is a small Phase 2 trial with only 48 participants, so results may not apply to everyone. Nintedanib can cause side effects like stomach issues, and it may not work better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TELANGIECTASIA, HEREDITARY HEMORRHAGIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Angiology Department, Lausanne University Hospital
COMPLETEDLausanne, Canton of Vaud, 1011, Switzerland
-
Clermont-Ferrand university hospital
RECRUITINGClermont-Ferrand, 63000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lyon University Hospital, Dpt of genetics
RECRUITINGBron, 69677, France
Contact Phone: •••-•••-•••• Email: •••••@•••••